Gilead Sciences Inc (GILD) Common Stock USD0.001

Sell:$107.87Buy:$107.88$0.32 (0.30%)

NASDAQ:0.46%
Market closed | Prices delayed by at least 15 minutes
Sell:$107.87
Buy:$107.88
Change:$0.32 (0.30%)
Market closed | Prices delayed by at least 15 minutes
Sell:$107.87
Buy:$107.88
Change:$0.32 (0.30%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Anitocabtagene autoleucel, Sacituzumab govitecan-hziy, and Domvanalimab and zimberelimab. Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. It operates in more than 35 countries worldwide.

Key people

Daniel P O'Day
Chairman of the Board, Chief Executive Officer
Andrew D. Dickinson
Chief Financial Officer
Deborah H. Telman
Executive Vice President - Corporate Affairs, General Counsel
Dietmar P. Berger
Chief Medical Officer
Johanna Mercier
Chief Commercial Officer
Anthony Welters
Lead Independent Director
Ted W. Love
Director
Jacqueline K. Barton
Independent Director
Jeffrey A. Bluestone
Independent Director
Sandra J. Horning
Independent Director
Click to see more

Key facts

  • EPIC
    GILD
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US3755581036
  • Market cap
    $133.35bn
  • Employees
    17,600
  • Shares in issue
    1.25bn
  • Exchange
    NASDAQ
  • Index
    S&P 500, NASDAQ 100 Index, TR Equity United States Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.